Dysfunctional Blood and Target Tissue CD4+CD25high Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation
Top Cited Papers
- 1 January 2005
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 174 (1) , 164-173
- https://doi.org/10.4049/jimmunol.174.1.164
Abstract
The balance between regulatory and effector functions is important for maintaining efficient immune responses, while avoiding autoimmunity. The inflammatory skin disease psoriasis is sustained by the ongoing activation of pathogenic effector T cells. We found that a CD4+ T lymphocyte subpopulation in peripheral blood, phenotypically CD25high, CTLA-4+, Foxp3high (regulatory T (Treg) cells), is deficient in its suppressor activity in psoriasis. This was associated with accelerated proliferation of CD4+ responder T cells in psoriasis, the majority of which expressed CXCR3. Nevertheless, criss-cross experiments isolated the defect to psoriatic Treg cells. To examine Treg cells in a nonlymphoid tissue of a human T cell-mediated disease, Treg cells were also analyzed and isolated from the site of inflammation, psoriatic lesional skin. At the regulatory vs effector T cells ratios calculated to be present in skin, however, the psoriatic Treg cell population demonstrated decreased suppression of effector T cells. Thus, dysfunctional blood and target tissue CD4+CD25high Treg cell activity may lead to reduced restraint and consequent hyperproliferation of psoriatic pathogenic T cells in vivo. These findings represent a critical component of human organ-specific autoimmune disease and may have important implications with regard to the possible therapeutic manipulation of Treg cells in vivo.Keywords
This publication has 56 references indexed in Scilit:
- Selective targeting of T cell subsets: focus on alefacept – a remittive therapy for psoriasisExpert Opinion on Biological Therapy, 2002
- Treatment of Severe Psoriasis With Anti-CD25 Monoclonal AntibodiesArchives of Dermatology, 2000
- CD69, HLA-DR and the IL-2R Identify Persistently Activated T Cells in Psoriasis Vulgaris Lesional Skin: Blood and Skin Comparisons by Flow CytometryJournal of Autoimmunity, 2000
- Effects of cyclosporine on cytokines and cytokine receptors in psoriasisJournal of the American Academy of Dermatology, 1995
- Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes.Journal of Clinical Investigation, 1995
- T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted productsEuropean Journal of Immunology, 1994
- The mechanisms of action of cyclosporin A in the treatment of psoriasisImmunology Today, 1993
- The Role of Immune System in the Pathogenesis of PsoriasisJournal of Investigative Dermatology, 1990
- Immunological responses of patients with psoriasis and the effect of treatment with methotrexateBritish Journal of Dermatology, 1975
- Abnormal Cell Proliferation in Psoriasis**From the Department of Dermatology, University of Miami School of Medicine, Miami, Florida.Journal of Investigative Dermatology, 1968